scholarly journals Fall Risk and Related Factors in Systemic Lupus Erythematosus

2017 ◽  
Vol 32 (3) ◽  
pp. 216-220 ◽  
Author(s):  
Meltem Alkan Melikoğlu
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Fall Risk ◽  
Systemic Lupus ◽  
Related Factors

The prevalence of oral mucosal lesions and related factors in 188 patients with systemic lupus erythematosus

Lupus ◽  
2012 ◽  
Vol 21 (12) ◽  
pp. 1312-1315 ◽  
Author(s):  
M Khatibi ◽  
AH Shakoorpour ◽  
Z Moosavian Jahromi ◽  
A Ahmadzadeh
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Related Factors ◽  
Oral Mucosal Lesions ◽  
Mucosal Lesions

scholarly journals THE PRECIPITIN REACTION BETWEEN DNA AND A SERUM FACTOR IN SYSTEMIC LUPUS ERYTHEMATOSUS

1959 ◽  
Vol 109 (1) ◽  
pp. 97-114 ◽  
Author(s):  
H. R. G. Deicher ◽  
H. R. Holman ◽  
H. G. Kunkel
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Double Diffusion ◽  
Serum Factor ◽  
Systemic Lupus ◽  
Related Factors ◽  
Antigenic Properties ◽  
Γ Globulins ◽  
Specific Reactions ◽  
Precipitating Factor

The sera of certain patients with systemic lupus erythematosus contain an antibody-like substance capable of reacting with highly purified DNA preparations from widely divergent sources. Precipitin reactions have been demonstrated by double diffusion in agar and quantitative precipitin curves have been obtained. Complement was observed to be fixed in the reaction. Evidence was obtained that the serum factor possessed antigenic properties similar to those of γ-globulins and migrated with this fraction on zone electrophoresis. The interaction of this factor with DNA exhibited certain specific characteristics which differ considerably from non-specific reactions between DNA and proteins in general. The DNA-precipitating factor appeared to be one of a number of related factors reacting with nuclear constituents of many different cells. It differed in certain respects from the "LE factor" which is responsible for the formation of "LE cells." The accumulated evidence, although not yet conclusive, favors the concept that the precipitating factor represents an antibody to DNA, and that it is one of a number of autoantibodies elicited in this disease.

Prevalence and Risk Factors for Liver Biochemical Abnormalities in Canadian Patients with Systemic Lupus Erythematosus

2011 ◽  
Vol 39 (2) ◽  
pp. 254-261 ◽  
Author(s):  
DARRYL HUANG ◽  
ELAHEH AGHDASSI ◽  
JIANDONG SU ◽  
JEFFREY MOSKO ◽  
GIDEON M. HIRSCHFIELD ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Laboratory Data ◽  
Systemic Lupus ◽  
Drug Induced ◽  
Related Factors ◽  
University Of Toronto ◽  
American College Of Rheumatology ◽  
Dsdna Antibody ◽  
Biochemical Abnormalities

Objective.To determine the prevalence of abnormal liver enzymes in patients with systemic lupus erythematosus (SLE) and whether further investigations were done, and the differences in SLE-related and/or metabolic factors in patients with and without liver biochemical abnormalities.Method.Patients from the University of Toronto Lupus Clinic who met at least 4 of the American College of Rheumatology classification criteria for SLE and had 1.5 times the upper limit for aspartate transaminase or alanine transaminase on 2 consecutive visits within a 2-year period were matched with controls for age, sex, and SLE duration. Demographic, clinical, and laboratory data were extracted at the time of the first appearance of liver enzyme abnormality for the cases and at the reference point for the controls.Results.From the 1533 patients reviewed, 134 (8.7%) met the inclusion criteria. Thirty of these patients were evaluated by a hepatologist, 75 had imaging studies (41 were done specifically for liver investigation), and 13 had liver biopsies. Results based on these investigations showed 31 fatty livers, 35 cases of drug-induced hepatotoxicity, 10 autoimmune etiologies, and 3 cases of viral hepatitis. Compared to controls, cases were higher in body mass index, anti-dsDNA antibody, prevalence of hypertension, antiphospholipid syndrome, and use of immunosuppressive medication, especially azathioprine and methotrexate; they were lower in IgM.Conclusion.Metabolic abnormalities such as obesity and hypertension and hepatotoxic effects of medication used to treat SLE may contribute more than SLE-related factors to liver biochemical abnormalities in patients with SLE.

Irritable bowel syndrome-type symptoms in female patients with mild systemic lupus erythematosus: frequency, related factors and quality of life

2013 ◽  
Vol 25 (12) ◽  
pp. 958-966 ◽  
Author(s):  
M. García Carrasco ◽  
C. Mendoza Pinto ◽  
A. López Colombo ◽  
S. Méndez Martínez ◽  
R. Andari Sawaya ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systemic Lupus Erythematosus ◽  
Irritable Bowel Syndrome ◽  
Lupus Erythematosus ◽  
Syndrome Type ◽  
Systemic Lupus ◽  
Related Factors ◽  
Female Patients ◽  
Irritable Bowel

scholarly journals The prevalence of oral mucosal lesions and related factors in systemic lupus erythematosus patients

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Mayssoun Kudsi ◽  
Louei Darjazini Nahas ◽  
Rama Alsawah ◽  
Ahmad Hamsho ◽  
Abdullah Omar
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Examination ◽  
Lupus Erythematosus ◽  
Oral Lesions ◽  
Systemic Lupus ◽  
Related Factors ◽  
Wide Range ◽  
Significant Difference ◽  
Oral Mucosal Lesions ◽  
Mucosal Lesions

Abstract Background Systemic lupus erythematosus (SLE) is a chronic inflammatory multi systematic disease of unknown aetiology. SLE has a wide range of symptoms. The most common symptoms are joint pain, skin rash and fever. Oral lesions in SLE manifest in a variety of forms, such as oral mucosal ulceration, mouth burns, xerostomia and salivary gland diseases, temporomandibular joint disease, periodontal disease, dysgeusia, white lesions, oedema, bleeding and petechiae. Objective This study was conducted to evaluate the prevalence of oral mucosal lesions and their related factors in patients with SLE, giving the lack of comprehensive statistical data in Syria and the differences between reported prevalence. Patients and methods A cross-sectional study was performed in the Al-Mouassat University Hospital in Damascus. Patients were evaluated appropriating observation, clinical examination, completing questionnaires, studying patient’s medical records and paraclinical laboratory tests if required. Four types of oral lesions were evaluated: ulcer, erythema, white plaque and spots. The diagnosis of these lesions was made according to observation and clinical examination, and the location of each lesion was also recorded. Data were analysed using SPSS version 16.0. Result In this study, 42 (70% %) out of 60 patients (38 women and 4 men) had oral lesions, while 18 (30%) had none. The most common areas for the lesions were the buccal mucosa (26.1%) and the lips (14.2%). Of the 42 patients with oral lesions, 12 (27.6%) showed ulcers. There was a significant relationship between the following factors and oral lesions: oral hygiene status, the duration of the disease involvement, frequency of pregnancies, the amount of daily use of corticosteroids without significant difference between dosage groups, and medications used for SLE treatment other than corticosteroids (p < 0.008) without mentioned names or dosages. Conversely, age, sex, cigarette smoking and medications other than those used for SLE treatment were not significantly related to the presence of oral lesions (p value was greater than 0.05 in all subjects).

scholarly journals Understanding Nonadherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus

2019 ◽  
Vol 46 (10) ◽  
pp. 1309-1315 ◽  
Author(s):  
Lucy H. Liu ◽  
Helene B. Fevrier ◽  
Robert Goldfien ◽  
Anke Hemmerling ◽  
Lisa J. Herrinton
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Census Data ◽  
Medical Center ◽  
Medication Possession Ratio ◽  
World Health ◽  
Systemic Lupus ◽  
Related Factors ◽  
Adherence To Medication ◽  
Adherence Support

Objective.Hydroxychloroquine (HCQ) is a cornerstone to managing systemic lupus erythematosus (SLE), yet adherence to medication is poor. We sought to measure the association of adherence with 5 “dimensions of adherence” as articulated by the World Health Organization for chronic conditions: the patient’s socioeconomic status, and patient-, condition-, therapy-, and healthcare system–related factors. Our longterm goal is to generate evidence to design effective interventions to increase adherence.Methods.The retrospective cohort study included Kaiser Permanente Northern California patients ≥ 18 years old during 2006–2014, with SLE and ≥ 2 consecutive prescriptions for HCQ. Adherence was calculated from the medication possession ratio and dichotomized as < 80% versus ≥ 80%. Predictor variables were obtained from the electronic medical record and census data. We used multivariable logistic regression to estimate adjusted OR and 95% CI.Results.The study included 1956 patients. Only 58% of patients had adherence ≥ 80%. In adjusted analyses, socioeconomic variables did not predict adherence. Increasing age (65–89 yrs compared with ≤ 39 yrs: OR 1.44, 95% CI 1.07–1.93), white race (p < 0.05), and the number of rheumatology visits in the year before baseline (≥ 3 compared with 0 or 1: OR 1.47, 95% CI 1.18–1.83) were positively associated with adherence. The rheumatologist and medical center providing care were not associated with adherence.Conclusion.At our setting, as in other settings, about half of patients with SLE were not adherent to HCQ therapy. Differences in adherence by race/ethnicity suggest the possibility of using tailored interventions to increase adherence. Qualitative research is needed to elucidate patient preferences for adherence support.

Sign in / Sign up

Export Citation Format

Share Document